Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares OutstandingShares Outstanding
Ratios

VYNE Therapeutics (VYNE) Accumulated Depreciation & Amortization (2018 - 2025)

VYNE Therapeutics' Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $23000.0 for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 475.0% year-over-year to $23000.0; the TTM value through Dec 2025 reached $23000.0, up 475.0%, while the annual FY2025 figure was $23000.0, 475.0% up from the prior year.
  • Accumulated Depreciation & Amortization reached $23000.0 in Q4 2025 per VYNE's latest filing, up from $12000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $109000.0 in Q4 2021 to a low of $4000.0 in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 4 years is $42333.3, with a median of $17500.0 recorded in 2025.
  • Peak YoY movement for Accumulated Depreciation & Amortization: crashed 68.04% in 2021, then skyrocketed 475.0% in 2025.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $109000.0 in 2021, then fell by 8.26% to $100000.0 in 2022, then tumbled by 96.0% to $4000.0 in 2024, then surged by 475.0% to $23000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Accumulated Depreciation & Amortization are $23000.0 (Q4 2025), $12000.0 (Q2 2025), and $6000.0 (Q1 2025).